Journal of Oncology

Research Article

Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma

Table 4

Multivariate analysis to identify independent risk factors of progression-free survival and overall survival in CTC-positive HCC patients.


Variable	Progression-free survival		Overall survival
Variable	HR (95% CI)	value	HR (95% CI)	value

Tumor number (>3)	3.059 (0.672∼13.394)	0.148	0.380 (0.005∼30.134)	0.664
Tumor size (>3 cm)	0.348 (0.051∼2.395)	0.284	2098.606 (0∼5.31610^⁹)	0.934
Edmonson stage (III-IV)	0.693 (0.136∼3.523)	0.659	1.297 (0.068∼24.657)	0.863
TNM stage (III-IV)	1.394 (0.340∼5.721)	0.644	8.755 (0.272∼281.503)	0.220
AFP (>400 ng/ml)	2.047 (0.340∼12.329)	0.434	1.944 (0.04∼91.723)	0.735
HBsAg (+)	0.348 (0.054∼2.259)	0.269	0.045 (0.000∼61.85)	0.216
Pretransplant RFA (yes)	0.076 (0.008∼0.724)	0.025	0.140 (0.002∼11.449)	0.382

Bold values indicate statistical significance. AFP: alpha-fetoprotein; CTC: circulating tumor cells; HBsAg: hepatitis B surface antigen; HCC: hepatocellular carcinoma; MVI: microvascular invasions; PVT: portal vein thrombosis; RFA: radiofrequency ablation; UCSF: University of California San Francisco.